SCHEMBL64267

SCHEMBL64267

CN(C)C(=O)C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccccn2)c(O)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.40
TSHR P16473 4/20 0.40
MAPK1 P28482 3/20 0.40
KDM4E B2RXH2 4/20 0.39
LMNA P02545 3/20 0.39
PKM P14618 2/20 0.39
SMN1; SMN2 Q16637 5/20 0.38
HTT P42858 3/20 0.38
USP2 O75604 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
PTPN11 Q06124 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 2/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL53142 0.89 CYP2C9 (0.45) ALDH1A1KDM4EPKMHTTNPSR1
SCHEMBL64354 0.87 CYP2C9 (0.37) MAPTCYP2C9
SCHEMBL64262 0.86 HPGD (0.39) CYP2C9NPC1HPGDRAB9A
SCHEMBL64544 0.86 CYP2C9 (0.41) ALDH1A1KDM4ELMNASMN1; SMN2TP53
SCHEMBL63534 0.86 HTT (0.40) ALDH1A1TSHRMAPK1KDM4ELMNA
SCHEMBL64597 0.85 CYP2C9 (0.47) CYP2C9
SCHEMBL64529 0.85 ALDH1A1 (0.41) ALDH1A1TSHRPKMSMN1; SMN2MAPT
SCHEMBL62748 0.85 CYP2C9 (0.37) MAPK1TP53MAPTCYP2C9HPGD
SCHEMBL64273 0.85 CYP2C9 (0.39) ALDH1A1TSHRKDM4ELMNAMAPT
SCHEMBL63942 0.85 LIPG (0.39) CYP2C9CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ALDH1A1 539/4885TSHR 4845/4885MAPK1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.